The company has not filed an annual or quarterly report since its Q3 FY2023 10-Q, filed May 9, 2023. Its latest SEC filing is a 15-12G from Jun 27, 2023.
10-Q for Q3 FY2023, filed May 9, 2023
The sections below describe the company as of the FY2022 annual report.
Develops antibody drug candidates and genetics-based diagnostic tests for immune-mediated diseases, including inflammatory bowel disease, for patients and treating physicians.
10-K for FY2022, filed Feb 28, 2023We are a clinical-stage biotechnology company pioneering a precision medicine approach to the discovery, development, and commercialization…View ↗
Our lead product candidate, PRA023, is a humanized IgG1 mAb that has been shown to bind and neutralize both the active trimeric form and…View ↗
We believe that Prometheus360 can potentially revolutionize the drug development and treatment paradigm for patients by utilizing…View ↗
Pharmaceutical collaborators pay upfront license fees, development, regulatory and commercial milestones, and for research and development services; the company also earns royalties when licensed products are sold.
10-K for FY2022, filed Feb 28, 2023
$6.8M
10-K for FY2022, filed Feb 28, 2023
$6.8M ↗
Plans to market its lead therapy and diagnostic test directly through a dedicated sales force to selected specialist physicians in the United States, typically affiliated with hospitals and medical centers. For another drug program, Falk holds exclusive commercialization rights in Europe, Australia and New Zealand.
10-K for FY2022, filed Feb 28, 2023
No. It lost $141.8M in FY2022.
10-K for FY2022, filed Feb 28, 2023
−$145.8MView ↗
10-K for FY2022, filed Feb 28, 2023
−$141.8MView ↗
10-K for FY2022, filed Feb 28, 2023
−$126MView ↗
10-Q for Q3 FY2023, filed May 9, 2023
−$40.9MView ↗
8-K, filed Jun 16, 2023
On June 16, 2023 (the “Closing Date”), Prometheus Biosciences, Inc., a Delaware corporation (“Prometheus”), completed the previously…View ↗
Competes with Takeda, AbbVie, Johnson & Johnson, Pfizer, Bristol-Myers Squibb, Roivant Sciences, Eli Lilly, Abivax, Amgen, Applied Molecular Transport, Arena Pharmaceuticals, AstraZeneca Pharmaceuticals, Gilead Sciences, Gossamer Bio, Landos Biopharma, Morphic Holding, Merck &, Novartis International, and Protagonist Therapeutics
10-K for FY2022, filed Feb 28, 2023If approved for the treatment of patients with moderate-to-severe IBD, PRA023 and our other development programs would compete with…View ↗
Loading...
